Biomerica (NASDAQ:BMRA) Stock Passes Below Two Hundred Day Moving Average of $0.97

Shares of Biomerica, Inc. (NASDAQ:BMRAGet Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.97 and traded as low as $0.70. Biomerica shares last traded at $0.72, with a volume of 59,331 shares trading hands.

Biomerica Stock Down 1.2 %

The business’s 50-day moving average price is $0.97 and its 200 day moving average price is $0.96. The company has a market capitalization of $11.99 million, a P/E ratio of -1.93 and a beta of -1.04.

Biomerica (NASDAQ:BMRAGet Free Report) last released its quarterly earnings data on Friday, April 12th. The company reported ($0.11) EPS for the quarter. Biomerica had a negative net margin of 117.46% and a negative return on equity of 64.00%. The firm had revenue of $1.02 million during the quarter.

Hedge Funds Weigh In On Biomerica

A hedge fund recently raised its stake in Biomerica stock. Russell Investments Group Ltd. increased its position in Biomerica, Inc. (NASDAQ:BMRAFree Report) by 15.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 201,563 shares of the company’s stock after acquiring an additional 26,288 shares during the quarter. Russell Investments Group Ltd. owned about 1.20% of Biomerica worth $252,000 at the end of the most recent quarter. 22.28% of the stock is currently owned by hedge funds and other institutional investors.

About Biomerica

(Get Free Report)

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.

Further Reading

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.